Strs Ohio Has $943,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Strs Ohio lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,100 shares of the biopharmaceutical company’s stock after selling 3,100 shares during the quarter. Strs Ohio’s holdings in Catalyst Pharmaceuticals were worth $943,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 306.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 3,829 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $123,000. PNC Financial Services Group Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 42.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 11,241 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 3,354 shares during the period. CenterBook Partners LP increased its holdings in shares of Catalyst Pharmaceuticals by 20.0% during the 3rd quarter. CenterBook Partners LP now owns 13,577 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 2,259 shares during the last quarter. Finally, Cerity Partners LLC raised its stake in Catalyst Pharmaceuticals by 11.5% in the 4th quarter. Cerity Partners LLC now owns 17,231 shares of the biopharmaceutical company’s stock valued at $290,000 after acquiring an additional 1,780 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on CPRX. HC Wainwright reiterated a “buy” rating and issued a $24.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Bank of America initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They issued a “buy” rating and a $23.00 target price for the company. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Cantor Fitzgerald restated an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. Finally, Citigroup initiated coverage on Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They issued a “buy” rating and a $27.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $26.43.

Insider Activity

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total value of $392,000.00. Following the completion of the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at $5,470,344.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.10% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 2.6 %

Catalyst Pharmaceuticals stock opened at $15.12 on Thursday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.09 and a 1-year high of $17.76. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of 24.79, a P/E/G ratio of 0.83 and a beta of 0.89. The firm has a 50 day simple moving average of $15.47 and a 200 day simple moving average of $14.60.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. The company had revenue of $110.57 million during the quarter, compared to analyst estimates of $105.78 million. On average, equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.